Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells (original) (raw)

• Ahmed NN, Franke TF, Bellacosa A, Datta K, Gonzalez-Portal ME, Taguchi T et al. (1993). The proteins encoded by c-akt and v-akt differ in post-translational modification, subcellular localization and oncogenic potential. Oncogene 8: 1957–1963.
  CAS PubMed Google Scholar
• Amaravadi R, Thompson CB . (2005). The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 115: 2618–2624.
  Article CAS PubMed PubMed Central Google Scholar
• Askham JM, Platt F, Chambers PA, Snowden H, Taylor CF, Knowles MA . (2010). AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K. Oncogene 29: 150–155.
  Article CAS PubMed Google Scholar
• Bachmann M, Moroy T . (2005). The serine/threonine kinase Pim-1. Int J Biochem Cell Biol 37: 726–730.
  Article CAS PubMed Google Scholar
• Banerjee A, Rothman PB . (1998). IL-7 reconstitutes multiple aspects of v-Abl-mediated signaling. J Immunol 161: 4611–4617.
  CAS PubMed Google Scholar
• Bleeker FE, Felicioni L, Buttitta F, Lamba S, Cardone L, Rodolfo M et al. (2008). AKT1(E17K) in human solid tumours. Oncogene 27: 5648–5650.
  Article CAS PubMed Google Scholar
• Brugge J, Hung MC, Mills GB . (2007). A new mutational AKTivation in the PI3K pathway. Cancer Cell 12: 104–107.
  Article CAS PubMed Google Scholar
• Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM et al. (2007). A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448: 439–444.
  Article CAS PubMed Google Scholar
• Chen JL, Fucini RV, Lacomis L, Erdjument-Bromage H, Tempst P, Stamnes M . (2005). Coatomer-bound Cdc42 regulates dynein recruitment to COPI vesicles. J Cell Biol 169: 383–389.
  Article CAS PubMed PubMed Central Google Scholar
• Chen JL, Limnander A, Rothman PB . (2008). Pim-1 and Pim-2 kinases are required for efficient pre-B-cell transformation by v-Abl oncogene. Blood 111: 1677–1685.
  Article CAS PubMed Google Scholar
• Danial NN, Rothman PB . (2000). JAK-STAT signaling activated by Abl oncogenes. Oncogene 19: 2523–2531.
  Article CAS PubMed Google Scholar
• Deutsch AJ, Aigelsreiter A, Staber PB, Beham A, Linkesch W, Guelly C et al. (2007). MALT lymphoma and extranodal diffuse large B-cell lymphoma are targeted by aberrant somatic hypermutation. Blood 109: 3500–3504.
  Article CAS PubMed Google Scholar
• Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K et al. (2001). Delineation of prognostic biomarkers in prostate cancer. Nature 412: 822–826.
  Article CAS PubMed Google Scholar
• Gong L, Unnikrishnan I, Raghavan A, Parmar K, Rosenberg N . (2004). Active Akt and functional p53 modulate apoptosis in Abelson virus-transformed pre-B cells. J Virol 78: 1636–1644.
  Article CAS PubMed PubMed Central Google Scholar
• Hammerman PS, Fox CJ, Birnbaum MJ, Thompson CB . (2005). Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival. Blood 105: 4477–4483.
  Article CAS PubMed PubMed Central Google Scholar
• Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, Benet I et al. (2000). Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med 191: 977–984.
  Article CAS PubMed PubMed Central Google Scholar
• Horn S, Bergholz U, Jücker M, McCubrey JA, Trümper L, Stocking C et al. (2008). Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells. Oncogene 27: 4096–4106.
  Article CAS PubMed Google Scholar
• Hu XF, Li J, Vandervalk S, Wang Z, Magnuson NS, Xing PX . (2009). PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis. J Clin Invest 119: 362–375.
  CAS PubMed PubMed Central Google Scholar
• Kharas MG, Fruman DA . (2005). ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res 65: 2047–2053.
  Article CAS PubMed Google Scholar
• Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM et al. (2008). Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest 118: 3038–3050.
  Article CAS PubMed PubMed Central Google Scholar
• Kim MS, Jeong EG, Yoo NJ, Lee SH . (2008). Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br J Cancer 98: 1533–1535.
  Article CAS PubMed PubMed Central Google Scholar
• Klejman A, Rushen L, Morrione A, Slupianek A, Skorski T . (2002). Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene 21: 5868–5876.
  Article CAS PubMed Google Scholar
• Landgraf KE, Pilling C, Falke JJ . (2008). Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain. Biochemistry 47: 12260–12269.
  Article CAS PubMed Google Scholar
• Li X, Monks B, Ge Q, Birnbaum MJ . (2007). Akt/PKB regulates hepatic metabolism by directly inhibiting PGC-1alpha transcription coactivator. Nature 447: 1012–1016.
  Article CAS PubMed Google Scholar
• Mahmoud IS, Sughayer MA, Mohammad HA, Awidi AS, EL-Khateeb MS, Ismail SI . (2008). The transforming mutation E17K/AKT1 is not a major event in B-cell-derived lymphoid leukaemias. Br J Cancer 99: 488–490.
  Article CAS PubMed PubMed Central Google Scholar
• Malanga D, Scrima M, De Marco C, Fabiani F, De Rosa N, De Gisi S et al. (2008). Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle 7: 665–669.
  Article CAS PubMed Google Scholar
• Manning BD, Cantley LC . (2007). AKT/PKB signaling: navigating downstream. Cell 129: 1261–1274.
  Article CAS PubMed PubMed Central Google Scholar
• Mohamedali A, Lea NC, Feakins RM, Raj K, Mufti GJ, Kocher HM . (2008). AKT1 (E17K) mutation in pancreatic cancer. Technol Cancer Res Treat 7: 407–408.
  Article CAS PubMed Google Scholar
• Muraski JA, Rota M, Misao Y, Fransioli J, Cottage C, Gude N et al. (2007). Pim-1 regulates cardiomyocyte survival downstream of Akt. Nat Med 13: 1467–1475.
  Article CAS PubMed Google Scholar
• Nieborowska-Skorska M, Hoser G, Kossev P, Wasik MA, Skorski T . (2002). Complementary functions of the antiapoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis. Blood 99: 4531–4539.
  Article CAS PubMed Google Scholar
• Oki S, Limnander A, Danial NN, Rothman PB . (2002). Functional involvement of Akt signaling downstream of Jak1 in v-Abl-induced activation of hematopoietic cells. Blood 100: 966–973.
  Article CAS PubMed Google Scholar
• Pasqualucci L, Neumeister P, Goossens T, Nanjangud G, Chaganti RS, Küppers R et al. (2001). Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 412: 341–346.
  Article CAS PubMed Google Scholar
• Riener MO, Bawohl M, Clavien PA, Jochum W . (2008). Analysis of oncogenic AKT1 pE17K mutation in carcinomas of the biliary tract and liver. Br J Cancer 99: 836.
  Article CAS PubMed PubMed Central Google Scholar
• Samuels Y, Diaz Jr LA, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I et al. (2005). Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7: 561–573.
  Article CAS PubMed Google Scholar
• Shoji K, Oda K, Nakagawa S, Hosokawa S, Nagae G, Uehara Y et al. (2009). The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. Br J Cancer 101: 145–148.
  Article CAS PubMed PubMed Central Google Scholar
• Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK et al. (1997). Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 16: 6151–6161.
  Article CAS PubMed PubMed Central Google Scholar
• Tao WJ, Lin H, Sun T, Samanta AK, Arlinghaus R . (2008). BCR-ABL oncogenic transformation of NIH 3T3 fibroblasts requires the IL-3 receptor. Oncogene 27: 3194–3200.
  Article CAS PubMed Google Scholar
• Vivanco I, Sawyers CL . (2002). The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489–501.
  Article CAS PubMed Google Scholar
• Zenz T, Döhner K, Denzel T, Döhner H, Stilgenbauer S, Bullinger L . (2008). Chronic lymphocytic leukaemia and acute myeloid leukaemia are not associated with AKT1 pleckstrin homology domain (E17K) mutations. Br J Haematol 141: 742–743.
  Article CAS PubMed Google Scholar
• Zhang F, Beharry ZM, Harris TE, Lilly MB, Smith CD, Mahajan S et al. (2009). PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells. Cancer Biol Ther 8: 846–853.
  Article CAS PubMed Google Scholar
• Zilberman DE, Cohen Y, Amariglio N, Fridman E, Ramon J, Rechavi G . (2009). AKT1 E17 K pleckstrin homology domain mutation in urothelial carcinoma. Cancer Genet Cytogenet 191: 34–37.
  Article CAS PubMed Google Scholar